The combined oral contraceptive pill (COCP), often referred to as the birth control pill or colloquially as "the pill", is a type of birth control that is designed to be taken orally by women. The pill contains two important hormones: progestin (a synthetic form of the hormone progestogen/progesterone) and estrogen (usually ethinylestradiol and 17β estradiol). When taken correctly, it alters the menstrual cycle to eliminate ovulation and prevent pregnancy. COCPs were first approved for contraceptive use in the United States in 1960, and are a very popular form of birth control. They are used by more than 100 million women worldwide  and by about 9 million women in the United States. From 2015 to 2017, 12.6% of women aged 15–49 in the US reported using COCPs, making it the second most common method of contraception in this age range (female sterilization is the most common method). Use of COCPs, however, varies widely by country, age, education, and marital status. For example, one third of women aged 16–49 in the United Kingdom currently use either the combined pill or progestogen-only pill (POP), compared with less than 3% of women in Japan (as of 1950–2014).Combined oral contraceptives are on the World Health Organizations List of Essential Medicines. The pill was a catalyst for the sexual revolution. Medical use
Contraceptive use
Combined oral contraceptive pills are a type of oral medication that were originally designed to be taken every day at the same time of day in order to prevent pregnancy.
Guaifenesin was studied as a method to improve the possibility of conception, by thinning and increasing the stretchability (improved spinnbarkeit) of the cervical mucus, during the few days before ovulation, thus facilitating sperm penetration.Results from a 2014 study by the Virginia Commonwealth Universitys Department of Pediatrics indicated that guaifenesin did not have significant impact on sputum production or clearance in upper respiratory infections. This was consistent with a 2014 study involving 378 adult and adolescent participants, which indicated guaifenesin had no significant effect as either mucolytic or expectorant compared to placebo: "Although the upper respiratory quality of life improved over the course of the study in both the [guaifenesin] and placebo groups, this improvement was not accompanied by changes in sputum properties". See also
Guaiacol
Guaifenesin/phenylephrine
Methocarbamol
Mephenoxalone
Oxomemazine/guaifenesin
Plastic bronchitis

References
External links
"Guaifenesin". Drug Information Portal. U.S. National Library of Medicine. "F.D.A. Study Worries Makers of Drugs". The New York Times. 20 October 1981.